AIMT

Aimmune Therapeutics, Inc.
AIMT

Overview Fund Activity
Delisted

AIMT was delisted on the 12th of October, 2020.

Back to rankings

58 hedge funds and large institutions have $551M invested in Aimmune Therapeutics, Inc. in 2015 Q3 according to their latest regulatory filings, with 58 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
58
Holders Change
+58
Holders Change %
–
% of All Funds
1.62%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
%
% of All Funds
0.06%
New
58
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Fidelity Investments
1
Fidelity Investments
Massachusetts
$154M
2
FCMI
2
Foresite Capital Management II
California
$104M
3
AC
3
Aisling Capital
New York
$71.4M
4
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$31.4M
5
PHS
5
PFM Health Sciences
California
$25.2M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Shares
Change %
BNP Paribas Financial Markets
51
BNP Paribas Financial Markets
France
$52.3K +$52.3K +2,065 New
UBS Group
52
UBS Group
Switzerland
$15K +$15K +600 New
NFG
53
Next Financial Group
Texas
$12K +$12K +500 New
Royal Bank of Canada
54
Royal Bank of Canada
Ontario, Canada
$10K +$10K +400 New
Citigroup
55
Citigroup
New York
$9K +$9K +357 New
Morgan Stanley
56
Morgan Stanley
New York
$8K +$8K +300 New
SFM
57
Sphera Funds Management
Israel
$5K +$5K +200 New
ClearBridge Investments
58
ClearBridge Investments
New York
$5K +$5K +200 New
1 2
3